Supercapsular经皮辅助全髋关节入路在随机临床试验中未显示优于传统后入路的临床优势
这项随机对照试验将46例全髋关节置换术患者分为SuperPATH入路组(25例)和后入路组(21例),比较术后早期功能、患者报告结局、阿片类药物消耗和疼痛。结果显示两组在计时起立行走测试、计时爬梯测试、Oxford髋关节评分、疼痛评分、恢复工作和弃用助行器时间上均无显著差异,SuperPATH组仅在前2周阿片类药物消耗较低,但并发症更多。作者认为SuperPATH入路不应常规用于临床,直至有足够把握度的试验显示患者相关终点的临床重要差异。
要点
- SuperPATH组与后入路组在术后100天的TUG和TSC测试中无显著差异。
- 两组Oxford髋关节评分在所有术后时间点均无差异。
- SuperPATH组前2周阿片类药物消耗低于后入路组,但第4周无差异,且并发症更多。
核心结论
- SuperPATH入路相比后入路无临床优势,并发症更多,仅显示短期疼痛减轻。
- 作者认为在足够把握度的试验显示患者相关终点的临床重要差异之前,该入路不应常规用于临床实践。
研究设计与样本
- 随机对照试验,2017年2月至2019年5月共筛查101例符合纳入标准的患者,招募46例(46%),手术当天随机分组:SuperPATH组25例(54%),后入路组21例(46%)。
- SuperPATH技术利用臀中肌与外旋肌之间的平面,保留梨状肌和关节囊上方;后入路涉及松解短外旋肌和部分松解股方肌,保留臀大肌止点。
- 术后随访24个月以观察并发症,两组在BMI、性别、ASA分级、手术侧别或诊断上无差异。
主要发现
- 术后100天TUG时间:SuperPATH组8.9±2.6秒 vs 后入路组8.7±2.2秒(平均差异-0.2秒[95%CI -1.8至1.4];p=0.98),其他时间点结果相似。
- 术后100天TSC时间:SuperPATH组11.6±4.7秒 vs 后入路组10.8±3.6秒(平均差异-0.7秒[95%CI -3.5至2.1];p=0.88),所有时间点两组无差异。
- 术后6周Oxford髋关节评分:SuperPATH组36±5.9分 vs 后入路组38±8.6分(平均差异1.7分[95%CI -2.7至6.1];p=0.51);术后3个月:SuperPATH组42±6.7分 vs 后入路组41±10.2分(平均差异0.7分[95%CI -6.2至4.9];p=0.34),所有术后时间点无差异。
- 疼痛评分在所有测试时间点无差异(平均差异1[95%CI -0.2至2.2];p=0.102);后入路组前2周总阿片类药物消耗高于SuperPATH组(平均差异6[95%CI 2.3至9.9];p=0.001),但第4周两组无差异(平均差异0.4[95%CI -0.5至1.4];p=0.36)。
- 恢复工作时间:SuperPATH组 vs 后入路组平均差异6天[95%CI -29至41];p=0.74;弃用助行器时间:平均差异0.9天[95%CI -25至27];p=0.94。
临床怎么用
- 作者认为SuperPATH入路不应常规用于临床实践,直至有足够把握度的试验显示患者相关终点的临床重要差异。
- 作者认为术后恢复的改善可能是多因素的,不依赖于入路的侵入性。
局限性
- 作者称本研究为小样本随机对照试验,其结果可用于计算未来样本量。
- 作者指出任何 favoring SuperPATH 入路的差异可能很小且短暂。
- 作者认为需要足够把握度的试验来显示患者相关终点的临床重要差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The supercapsular percutaneously assisted total hip (SuperPATH) approach was designed to be a less-invasive surgical approach to THA. This approach may have advantages, including less pain, more rapid mobilization, and shorter hospital length of stay. However, few published studies have compared the SuperPATH technique to existing standard approaches in a randomized, controlled manner. QUESTIONS/PURPOSES: In this study, we asked: (1) Do patients with SuperPATH demonstrate improved early function, using the timed up and go (TUG) and timed stair climbing (TSC) tests as instruments for assessment during the first 100 days postoperatively? (2) Are patient-reported outcomes, in the form of Oxford Hip Scores, better for the SuperPATH group during the first 3 months postoperatively? (3) Are opioid consumption and pain score in the first month postoperatively different between patients undergoing SuperPATH and patients undergoing a standard posterior approach? (4) Are patients with SuperPATH able to discontinue using mobility aids and return to work more quickly? METHODS: Between February 2017 and May 2019, 46% (46 of 101) of patients were recruited among 101 patients who met our inclusion criteria. Those 46 patients were randomized into two groups on the day of surgery; 54% (25 of 46) were assigned to the study group (SuperPATH approach) and 46% (21 of 46) were assigned to the control group (posterior approach). The SuperPATH technique uses the plane between the gluteus medius and the external rotators while preserving the piriformis and the superior aspect of the capsule. A percutaneous accessory portal is required for acetabular reaming and cup insertion. The posterior approach involves releasing short rotators and partially releasing the quadratus femoris while retaining the gluteus maximus's insertion site. The two groups did not differ in BMI, gender, American Society of Anesthesiologists class, surgical side, or diagnosis. The length of stay, component position, and blood loss were similar between the groups, but the operative time was longer in the SuperPATH group than in the group with the posterior approach. One patient from the control group was lost to follow-up and was excluded. Three patients in the study group had complications. The TUG and TSC tests are timed tasks for the patient. In the TUG test, patients stand from sitting, walk 3 meters and turn, walk back, and sit down. The TSC test measures the time taken to ascend and descend 10 steps. Patients were followed for 24 months for any complications. RESULTS: The TUG time at 100 days was 8.9 ± 2.6 seconds in the SuperPATH group and 8.7 ± 2.2 seconds in the posterior group (mean difference -0.2 seconds [95% CI -1.8 to 1.4]; p = 0.98); results were similar at other timepoints. The TSC time at 100 days was 11.6 ± 4.7 seconds in the SuperPATH group and 10.8 ± 3.6 seconds in the posterior group (mean difference -0.7 seconds [95% CI -3.5 to 2.1]; p = 0.88), and there were no differences between the two groups at all timepoints. The Oxford Hip Score showed no difference at any point postoperatively. At 6 weeks, it was 36 ± 5.9 points in the SuperPATH group and 38 ± 8.6 in the posterior group (mean difference 1.7 points [95% CI -2.7 to 6.1]; p = 0.51). At 3 months, it was 42± 6.7 points in the SuperPATH group and 41 ± 10.2 points in the posterior group (mean difference 0.7 points [95% CI -6.2 to 4.9]; p = 0.34). Patients' pain scores did not show any differences at all tested timepoints (mean difference 1 [95% CI -0.2 to 2.2]; p = 0.102). Total opioid consumption in the posterior group was higher in the first 2 weeks than that in the SuperPATH group (mean difference 6 [95% CI 2.3 to 9.9]; p = 0.001), but there was no difference in either group by week 4 (mean difference 0.4 [95% CI -0.5 to 1.4]; p = 0.36). There was no difference in return to work between the SuperPATH group and the posterior approach group (mean difference 6 days [95% CI -29 to 41]; p = 0.74). Discontinuation of mobility aids was similar between the two groups (mean difference 0.9 days [95% CI -25 to 27]; p = 0.94). CONCLUSION: The SuperPATH approach had no clinical advantages over the posterior approach, resulted in more complications, and only showed a short-term reduction in pain. The results of our small randomized controlled trial can be used to calculate future sample sizes, but our data suggest that any differences favoring the SuperPATH approach are likely to be small and transient. This approach should not be used routinely in clinical practice until an adequately powered trial shows clinically important differences in patient-relevant endpoints. The improved postoperative recovery is likely multifactorial and not dependent on the invasiveness of the approach. LEVEL OF EVIDENCE: Level II, therapeutic study.
引用
- Khoja YT, Habis AA, Wood GCA, et al. The Supercapsular Percutaneously Assisted Total Hip Approach Does Not Provide Any Clinical Advantage Over the Conventional Posterior Approach for THA in a Randomized Clinical Trial. Clin Orthop Relat Res. 2022. PMID: 36350098. doi:10.1097/CORR.0000000000002449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。